Replies to post #514645 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

When the foreign website endpoints were changed, the stock went up a major amount. So, when the endpoints were not changed in the U.S. long before NYAS, the stock went down after TLD was provided there. Crash Overide said the endpoints were updated a week in advance, but, if true, somehow clinicaltrials.gov did not publish it in the normal course of time, and it instead languished for many days until it was published long after NYAS. This all fell to the benefit of some traders that apparently knew NWBO was going to be left naked without a JA and without a timely clin trials update, and knew the PFS negative result would be the first shared result in the slides — in the latter case, it appears Senti shared the forensics of the event demonstrated price crash started before slides were made available.

[biosectinvestor]

Agreed H. The fact is the market generally did not care about those endpoints not being updated on 5/10. The issue was failure to publish and PR, still being under the embargo, and Adam Feuerstein’s false assertions. The US trial database was only an issue to those of us who know about it and then only a technicality. The traders were getting out long before that was made an issue by social media posters as a gotcha. The reality is, the various sites that republished summaries of Adam’s article simply were caught off-guard presuming that he would be honest, and that’s when some here got their underwear twisted over the US clinical sites database update, but that was absolutely and clearly not what “moved the market” on 5/10. That is more of the same nonsense that short traders sling and some longs love to bathe in it.

And the mere act of updating it would then have moved the market if the market cared about that detail. The fact is there was no publication and people who pumped the heck out of the stock on Twitter and social media leading up to 5/10 were wrong and had egg on their face. Blaming the company for things like this makes them feel better. But the reality is, what those people started saying as soon as that was scheduled, on social media, did not happen as they thought. Understandable, but they were wrong.

The market reacted to THAT, plus Adam Feuerstein’s extremely misleading publication of what was in the presentation since most of the market was not going to pay $100 or more to see such a presentation and no one of the shareholders has a social media following that in any possible proximity matches Adam’s immediate reach when he publishes a column via an arm of the Boston Globe.